(Q39069585)

8 September 2017

title

Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care (English)

1 reference

8 September 2017

Antonio M Grimaldi

2

0 references

Paolo Antonio Ascierto

series ordinal

6

object named as

Paolo A Ascierto

1 reference

8 September 2017

1

Ester Simeone

1 reference

8 September 2017

Lucia Festino

3

1 reference

8 September 2017

Vito Vanella

series ordinal

4

1 reference

8 September 2017

Marco Palla

series ordinal

5

1 reference

8 September 2017

language of work or name

1 reference

6 January 2017

1 reference

8 September 2017

1 reference

8 September 2017

volume

31

1 reference

8 September 2017

issue

1

1 reference

8 September 2017

page(s)

51-61

1 reference

https://scigraph.springernature.com/pub.10.1007/s40259-016-0208-z

8 September 2017

exact match

0 references

cites work

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

The evolution of melanoma resistance reveals therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Universes collide: combining immunotherapy with targeted therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Do BRAF inhibitors select for populations with different disease progression kinetics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-016-0208-Z

10.1007/S40259-016-0208-Z

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference